Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $27.81 in the prior trading day, Janux Therapeutics Inc (NASDAQ: JANX) closed at $28.51, up 2.52%. In other words, the price has increased by $2.52 from its previous closing price. On the day, 1.37 million shares were traded. JANX stock price reached its highest trading level at $28.75 during the session, while it also had its lowest trading level at $27.4.
Ratios:
Our goal is to gain a better understanding of JANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 47.03 and its Current Ratio is at 47.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.
On September 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $45.Stifel initiated its Buy rating on September 10, 2025, with a $45 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 28 ’25 when Meyer Andrew Hollman sold 16,665 shares for $30.06 per share. The transaction valued at 500,987 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 16,665 shares of JANX for $455,788 on Oct 28 ’25. On May 01 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,333 shares for $32.03 each. As a result, the insider received 106,745 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1713277952 and an Enterprise Value of 739457024. For the stock, the TTM Price-to-Sale (P/S) ratio is 3893.82 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 1684.412 whereas that against EBITDA is -5.178.
Stock Price History:
The Beta on a monthly basis for JANX is 2.82, which has changed by -0.47582275 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $21.73. The 50-Day Moving Average of the stock is 15.81%, while the 200-Day Moving Average is calculated to be 1.50%.
Shares Statistics:
The stock has traded on average 887.40K shares per day over the past 3-months and 1225550 shares per day over the last 10 days, according to various share statistics. A total of 59.30M shares are outstanding, with a floating share count of 54.30M. Insiders hold about 9.64% of the company’s shares, while institutions hold 106.31% stake in the company. Shares short for JANX as of 1760486400 were 8562496 with a Short Ratio of 9.65, compared to 1757894400 on 8301729. Therefore, it implies a Short% of Shares Outstanding of 8562496 and a Short% of Float of 20.47.
Earnings Estimates
Current recommendations for the stock of the company come from 12.0 analysts. The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.38 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$1.42 and -$3.19 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$3.11, with 13.0 analysts recommending between -$1.87 and -$5.5.
